Document 2877
 DOCN  M94A2877
 TI    Treatment of HIV-infected patients with advanced symptomatic disease
       with WF10 solution (TCDO).
 DT    9412
 AU    Busch HW; Christensen S; Reichelt D; Jahn S; Zidek W; Medizinische
       Poliklinik, WWU Munster, Germany.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):204 (abstract no. PB0245). Unique
       Identifier : AIDSLINE ICA10/94369698
 AB    OBJECTIVE: Since the chlorite-oxygen reaction product (TCDO) activates
       cellular phagocytosis and killer systems such as monocytes-macrophages,
       NK-cells and cytotoxic T-lymphocytes and has also been shown to exhibit
       significant virucidal activity against HIV-particles, our aim was to
       determine the clinical effect of WF10 solution (intravenous application
       form of TCDO) in HIV-infected patients who are intolerant to
       antiretroviral therapy. METHODS: 20 patients with advanced symptomatic
       HIV-infection, CD4 cell counts < 200/microliters, who were intolerant to
       AZT, ddC and ddI were included in a controlled study. All patients had
       two or more of the following symptoms: body temperature > 38 degrees C,
       night sweat and chills, > 10% weight loss, diarrhea, fatigue, PGL,
       Kaposi's sarcoma, history of candidiasis or herpes zoster. 5 of 10
       patients, whose data are presented in this abstract were p24 antigen
       positive. WF10 solution was administered by i.v. infusion at a dosage of
       0.5 ml/kg b.w. per day for 2 consecutive days and twice a day 0.25 ml/kg
       b.w. for 3 consecutive days (= one treatment cycle) every 3 weeks for up
       to 3 months (4 treatment cycles). RESULTS: First, during 13 weeks of
       follow up no severe adverse reactions were seen. Second, one p24 antigen
       (Ag) positive patient became negative, the average value of the p24 Ag
       positive patients decreased by 25% under baseline value (b.v.). In one
       case a p24 Ag negative patient became p24 positive, but was again
       negative at the end of the study. Third, while the average of CD4 cell
       count declined from 36 to 24/microliters, the average values of
       lymphocytes increased from 658 to 721/microliters and of T-cells from
       429 to 502/microliters. Furthermore, an increase of white blood cells
       from 2656 to 3353/microliters, of granulocytes from 1467 to
       2301/microliters and of thrombocytes from 170 to 201 x 103/microliters
       was observed. Fourth, due to a remarkable effect on clinical symptoms,
       the average of quality of life-index increased by 10% over b.v.
       CONCLUSIONS: The initiation of WF10-therapy in symptomatic HIV-infected
       patients with impaired immunity who are intolerant to AZT, ddC and ddI
       appears to be of benefit.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY  Adjuvants,
       Immunologic/*THERAPEUTIC USE  Antiviral Agents/*THERAPEUTIC USE
       Chlorine/*THERAPEUTIC USE  Human  HIV Infections/*DRUG THERAPY
       Immunity, Cellular/DRUG EFFECTS  Leukocyte Count  Oxides/*THERAPEUTIC
       USE  Treatment Outcome  T4 Lymphocytes  CLINICAL TRIAL  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).